We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
Read MoreHide Full Article
Gilead Sciences, Inc. (GILD - Free Report) announced its decision to not seek approval of filgotinib for the treatment of rheumatoid arthritis (RA) in the United States as it does not see a viable path for the drug for the same.
We note that filgotinib is already approved and marketed as Jyseleca (200 mg and 100 mg tablets) in Europe and Japan for the treatment of adults with moderately to severely active RA.
The company and partner Galapagos NV (GLPG - Free Report) announced that they will amend their existing arrangement for the commercialization and development of filgotinib. The decision to do so follows a type A meeting with the FDA to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA.
Based on the feedback received from the FDA during the NDA review process and in the Type A meeting, Gilead decided to not pursue FDA approval of filgotinib for RA.
While both companies continue to believe in the clinical profile of the 200 mg dose, Gilead has concluded that this dose is required to be competitive in RA in the United States. However, the 200 mg dose is unlikely to achieve approval for RA in the United States without conducting substantial additional clinical studies.
Per the amended agreement, Galapagos will assume sole responsibility in Europe for filgotinib in RA and all potential indications. Gilead will receive royalties from European sales of filgotinib.
The majority of activities supporting filgotinib in Europe are expected to be assumed by Galapagos by the end of 2021 through a phased transition. However, Gilead will retain commercial rights and remain the marketing authorization holder for filgotinib outside of Europe, including in Japan where filgotinib has recently been approved and is co-marketed with Eisai.
The studies evaluating filgotinib in psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-infectious uveitis were recently paused.
Nevertheless, both companies will continue to evaluate the potential of filgotinib to support patients living with Inflammatory Bowel Disease (IBD). Gilead will retain operational responsibility for the current trials in Crohn’s disease, while Galapagos will assume operational responsibility for ongoing studies in ulcerative colitis (UC).
Galapagos will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe. All commercial economics on filgotinib in Europe will be transferred to Galapagos as of Jan 1, 2022, subject to payment of tiered royalties of 8 to 15% of net sales in Europe to Gilead, starting 2024. Gilead has agreed to irrevocably pay Galapagos €160 million (split between a €110 million payment in 2021 and a €50 million payment in 2022) and is subject to certain adjustments for higher-than-budgeted development costs. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.
Gilead’s shares have lost 9.4% in the year so far against the industry’s growth of 9.2%
The massive decline in sales of its HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.
However, competition in the RA market is very stiff in the United States from AbbVie’s (ABBV - Free Report) Humira and Eli Lilly’s (LLY - Free Report) Olumiant, which are already approved as a treatment for RA.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Image: Bigstock
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
Gilead Sciences, Inc. (GILD - Free Report) announced its decision to not seek approval of filgotinib for the treatment of rheumatoid arthritis (RA) in the United States as it does not see a viable path for the drug for the same.
We note that filgotinib is already approved and marketed as Jyseleca (200 mg and 100 mg tablets) in Europe and Japan for the treatment of adults with moderately to severely active RA.
The company and partner Galapagos NV (GLPG - Free Report) announced that they will amend their existing arrangement for the commercialization and development of filgotinib. The decision to do so follows a type A meeting with the FDA to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for filgotinib in the treatment of RA.
Based on the feedback received from the FDA during the NDA review process and in the Type A meeting, Gilead decided to not pursue FDA approval of filgotinib for RA.
While both companies continue to believe in the clinical profile of the 200 mg dose, Gilead has concluded that this dose is required to be competitive in RA in the United States. However, the 200 mg dose is unlikely to achieve approval for RA in the United States without conducting substantial additional clinical studies.
Per the amended agreement, Galapagos will assume sole responsibility in Europe for filgotinib in RA and all potential indications. Gilead will receive royalties from European sales of filgotinib.
The majority of activities supporting filgotinib in Europe are expected to be assumed by Galapagos by the end of 2021 through a phased transition. However, Gilead will retain commercial rights and remain the marketing authorization holder for filgotinib outside of Europe, including in Japan where filgotinib has recently been approved and is co-marketed with Eisai.
The studies evaluating filgotinib in psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-infectious uveitis were recently paused.
Nevertheless, both companies will continue to evaluate the potential of filgotinib to support patients living with Inflammatory Bowel Disease (IBD). Gilead will retain operational responsibility for the current trials in Crohn’s disease, while Galapagos will assume operational responsibility for ongoing studies in ulcerative colitis (UC).
Galapagos will assume all development, manufacturing, commercialization and certain other rights for filgotinib in Europe. All commercial economics on filgotinib in Europe will be transferred to Galapagos as of Jan 1, 2022, subject to payment of tiered royalties of 8 to 15% of net sales in Europe to Gilead, starting 2024. Gilead has agreed to irrevocably pay Galapagos €160 million (split between a €110 million payment in 2021 and a €50 million payment in 2022) and is subject to certain adjustments for higher-than-budgeted development costs. In addition, Galapagos will no longer be eligible to receive any future milestone payments relating to filgotinib in Europe.
Gilead’s shares have lost 9.4% in the year so far against the industry’s growth of 9.2%
The massive decline in sales of its HCV franchise has prompted it to focus on the HIV franchise, Yescarta and other newer avenues.
However, competition in the RA market is very stiff in the United States from AbbVie’s (ABBV - Free Report) Humira and Eli Lilly’s (LLY - Free Report) Olumiant, which are already approved as a treatment for RA.
Gilead currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>